Associated Papers
Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML).
Wu J et al.
Cancer Biology & Therapy, 2019
Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia.
Zhang X et al.
Oncotarget, 2016
Select a paper to view details